Sensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations

Dow Jones

Yesterday

By Josh Beckerman

Sensei Biotherapeutics shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company.

Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year.

The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors.

On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 16, 2025 15:32 ET (19:32 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2576720659"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576720659\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576720659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 03:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576720659","market":"sg","top_or_hot":-1,"title":"Sensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company. \n</p>\n<p>\n  Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year. \n</p>\n<p>\n  The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors. \n</p>\n<p>\n  On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 16, 2025 15:32 ET (19:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensei Biotherapeutics Shares Rise Ahead of Scheduled Presentations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-17 03:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company. \n</p>\n<p>\n  Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year. \n</p>\n<p>\n  The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors. \n</p>\n<p>\n  On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 16, 2025 15:32 ET (19:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576720659","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576720659","pubTimestamp":1760643120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sensei Biotherapeutics shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company.Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year.The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors.On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNSE":"Sensei Biotherapeutics, Inc."},"translate_title":"Sensei Biotherapeutics股价在预定演示前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNSE":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nSensei Biotherapeutics shares were higher in advance of scheduled presentations by the cancer-focused biotechnology company. \n\n\n  Shares were recently up 29% to $17.70 on Thursday. Volume was more than 95,500 shares, compared with a 65-day average of 17,035. The stock is up about 78% this year. \n\n\n  The company said July 30 that data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug would be presented Oct. 17 at the European Society for Medical Oncology Congress 2025. It will present data for solnerstotug alone and in combination with Libtayo in patients with advanced solid tumors. \n\n\n  On Oct. 20, Sensei is scheduled to host a virtual key opinion leader event that will include an update on plans for Phase 2 studies. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2025 15:32 ET (19:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}